Shang Hai Zheng Quan Bao·2026-02-27 20:41Core Viewpoint - The company reported a significant reduction in net losses for the fiscal year 2025, driven by increased sales of its core product, Toripalimab injection (brand name: Tuoyi R), and effective cost management strategies [1][2][3]. Financial Data and Indicators - The estimated net loss attributable to the parent company for 2025 is approximately RMB 797.99 million, a decrease of about RMB 482.94 million or 37.70% compared to the previous year [1][5]. - The estimated net loss after excluding non-recurring gains and losses is approximately RMB 912.46 million, a decrease of about RMB 377.43 million or 29.26% year-on-year [1][5]. Business Performance and Financial Condition - Sales revenue from Toripalimab injection increased significantly by approximately 37.72% year-on-year, with all 12 approved indications included in the national medical insurance catalog [2][3]. - The company has expanded its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, and the European Union [2][3]. Operational Strategies - The company implemented a "quality improvement and efficiency enhancement" action plan, which led to a notable reduction in net losses while maintaining a focus on core pipeline advancements [3][5]. - The company is advancing multiple innovative drugs in clinical trials, including JS207, JS212, and JS213, and is exploring various combination therapies to maximize pipeline synergy [3][5].